Latest News on TechBio Revolution 🌳

Evotec’s New Enricture platform

Evotec’s New Enricture

Enricture by Evotec is new a rapid, cost effective, and low ⬇️ risk screening platform for efficient ligand discovery. 

Evotec’s 🆕 Enricture is a rapid, cost effective, and low ⬇️ risk screening platform for efficient ligand discovery. By combining Affinity Selection–Mass Spectrometry (ASMS) with proprietary AI/ML-driven hit enrichment, it accelerates your drug discovery journey without compromising quality (Enricture AI-Powered Hit ID Service Sheet).

It offers:

• ▶️ Smarter spend: >5️⃣0️⃣% lower investment than traditional HTS with reduced risk,

• ▶️ Faster Results: Cut timelines by >3️⃣0️⃣% from 3 months to just 2,

• ▶️ Intelligent Screening: Use of proprietary AI/ML algorithms for hit enrichment,

• ▶️ Built-in Expertise: Access to a cross functional team including Medicinal Chemistry and Computational Chemistry specialists, and

• ▶️ High Quality Library: Highly curated 4️⃣0️⃣0️⃣, 0️⃣0️⃣0️⃣ lead-like library.

Enricture follows a 3️⃣-stage process for primary hit selection and confirmation followed by AI/ML-driven hit enrichment:

• Stage 1: Primary HTS using ASMS & AI/ML plate selection

  Selection of primary hits : Assay development included/ 50,000 compounds selected for ASMS screening/ 2 rounds of AI/ML-driven compound selection with additional 100,000 compounds screened,

• Stage 2: Hit confirmation using ASMS

  Identification of confirmed hits: Cherry picking of selected hits (up to 450 compounds)/ confirmation of hit compounds plus control without target/ validation using LC-MS,

• Stage 3: AI/ML-driven hit enrichment

  Identify additional hits: Selection of 1,000 compounds using proprietary AI/ML (combining existing and new data)/ evaluation of 1,000 compounds with 10–12 compounds per well plus control without target/ validation using LC-MS.

Background

Evotec SE (ETR: EVT) is a global biotechnology company committed to advancing drug discovery and development with a premium data analysis platform, the PanHunter (a multi-omics data analysis platform), that is a web-based platform that combines peer-reviewed statistical analysis algorithms with the potential for ML and AI capabilities. They also have a proprietary molecular patient database (E.MPD, Evotec‘s Molecular Patient Database) with over 1️⃣5️⃣k samples and they also have PanOmics platform with over 2️⃣0️⃣0️⃣k samples (multi-omics data generation at an industrialized scale).

On April 24, 2025, Evotec announced substantial progress in its strategic research collaboration with Bristol Myers Squibb, which aims to develop a high-value molecular glue-based pipeline for addressing unmet medical needs (BMS Pays Evotec $75M for Molecular Glue Research Progress).

Moreover, Evotec SE just unveiled new strategy and provided 2025 guidance bolstered by strong Q4 2024 results (April 2025). In particular:

• 📍 Group revenues increased by 2️⃣% to €797.0 M (2023: €781.4 M); Q4 2024 revenues increased by 1️⃣0️⃣% to €221.2 M from €201.3 M in Q4 2023,

• 📍 Evotec’s Just – Evotec Biologics segment saw impressive growth, with revenues rising by 7️⃣1️⃣% year-over-year, contributing €185.6 M (2023: €108.4 m) to the overall topline,

• 📍 Total Shared R&D revenues decreased by 9️⃣% to €611.4 M (2023: €673.0 M),

• 📍 Expansion of technology partnership with Sandoz and new customers for long-term development and commercial manufacturing in Biologics,

• 📍 Progress and extension of multi-year collaboration with Bristol Myers Squibb in neuroscience and targeted protein degradation,

• 📍 New technology development partnership with Novo Nordisk to support next-generation cell therapies (Evotec and Novo Nordisk team up on cell therapies),

• 📍 New multi-year master research collaboration with Pfizer, initially focusing on early discovery research for metabolic and infectious diseases.

Finally on June 25, 2025, Evotec SE (NASDAQ:EVO) one of the 10 best healthcare penny stocks to buy according to analysts announced it would participate in the NURTuRE-AKI consortium to investigate acute kidney injury (AKI) and advance drug discovery through multi-omics approaches (Evotec (EVO) Joins NURTuRE-AKI Consortium to Advance Kidney Injury Drug Discovery).

• The NURTuRE-AKI consortium aims to establish the world’s largest patient cohort database for AKI with twofold objectives: 👉 to enhance understanding of its molecular mechanisms and 👉 to accelerate drug discovery.

• The consortium is supported by 💷4️⃣.7️⃣M from industry partners, including Evotec, AstraZeneca, and Nephrolyx GmbH, facilitated by Kidney Research UK. Professor Nick Selby, a key researcher, oversees the AKI research efforts within the NURTuRE initiative.

AI-Driven Drug Discovery With AMD, Absci And Oracle

Advanced Micro Devices (AMD) Partners With Absci And Oracle

Advanced Micro Devices recently formed a collaboration with Oracle Cloud Infrastructure and Absci.

Advanced Micro Devices announced a 🆕 collaboration with Oracle Cloud Infrastructure and Absci to advance AI-driven drug discovery, leveraging its cutting-edge hardware like the Instinct MI355X GPUs (Advanced Micro Devices (AMD) Partners In AI-Driven Drug Discovery With Absci And Oracle). This partnership (Absci joins Oracle and AMD for AI-led drug discovery (ABSI)), alongside AMD's alliances with Aligned and HCLTech, showcases its commitment to technological innovation.

Advanced Micro Devices, Inc (NASDAQ:AMD) is an American multinational corporation and technology company headquartered in Santa Clara, California and maintains significant operations in Austin, Texas. Is known for its semiconductor products, delivering processors and graphics units for data centers, gaming and embedded systems. The company specializes in high-performance computing solutions designed for AI-driven applications.

On January 8, 2025, AMD entered a strategic collaboration with Absci Corporation, including a 💲2️⃣0️⃣M investment to support the company’s AI-driven drug discovery efforts. By providing AMD Instinct accelerators and ROCm software, AMD is looking to help Absci optimize its AI solutions for biologic drug development, particularly in antibody design (Advanced Micro Devices (AMD) Invests in Absci for AI-Driven Drug Discovery with High-Performance Computing Solutions).

Qureight appointed Craig Rhodes

Qureight appoints Craig Rhodes as head of partnerships

Qureight has announced the appointment of Craig Rhodes as head of partnerships to lead strategic engagements with pharmaceutical organizations.

Qureight, a techbio company advancing the understanding of lung 🫁 and heart 🫀 disease through application of its AI-powered imaging and clinical data curation platform, has announced the appointment of Craig Rhodes as head of partnerships to lead strategic engagements with pharmaceutical organisations (Qureight appoints Craig Rhodes as head of partnerships).

Rhodes was formerly EMEA director of healthcare and life sciences at NVIDIA. He will support now the adoption and integration of the Qureight platform into clinical trial workflows. Qureight’s deep-learning image analysis and AI-powered data analytics platform enables real insights to be drawn from complex and diverse health data, including CT scans, physiological data and blood-based biomarkers to accelerate drug development and enhance outcomes for patients with lung and heart diseases, where there is high unmet medical need.

Qureight is a clinical data analytics company based in Cambridge UK. Working with healthcare institutions, technology companies and the pharmaceutical industry their platform allows the realization of new endpoints in clinical data. Their AI-powered technology stack enables collaborative analysis for imaging, clinical data, and biomarkers. Qureight's deep-learning platform will be used to analyze lung and heart imaging data.

$150M Series D For Enveda

Enveda harvests another 💲1️⃣5️⃣0️⃣M to advance nature-inspired drugs

Enveda closed its second $150M financing round of the year. The series D round moves Enveda’s total funding beyond $500M.

Enveda just closed its second $150M financing round of the year (Enveda harvests another $150M to advance nature-inspired drugs). The series D round, which moves Enveda’s total funding beyond $500M, positions the biotech to advance a crop of programs into the clinic behind its phase 1b eczema project. Enveda also raised a $130M series C round late last year, securing cash for the phase 1 trial of eczema project with ENV-294. Sanofi (Enveda Gains Backing from Sanofi to Advance AI-Driven Drug Discovery to Clinical Trials Bringing Total Series C Financing to $150M) added to the round back in February, bringing the total size of the series C up to $150M.

✅ Enveda Biosciences (Enveda Biosciences Inc) is unlocking the planet's chemistry to discover next-generation therapies, by using breakthroughs in ML, metabolomics and robotics, to index nature’s untapped chemical space for new drug discovery.

In June 2025, Enveda successfully completed 🏌️‍♂️ a Phase 1 safety testing of its AI-discovered oral anti-inflammatory drug candidate, marking a major milestone for AI-first drug development (Enveda Reports Favorable Phase 1 Safety for Novel Oral Anti-Inflammatory, Launches Phase 1b Trial in Atopic Dermatitis).

• ✅ ENV-294, is a novel oral therapeutic for atopic dermatitis, asthma, and beyond, that is a first-in-class anti-inflammatory small molecule derived from chemistry unearthed by Enveda’s platform. Based on the favorable safety and tolerability results in healthy volunteers, the Safety Review Committee endorsed advancement to a Phase 1b clinical trial evaluating ENV-294 in patients with atopic dermatitis.

• ✅ Phase 1b initiation is currently expected to begin in the second half of 2025.

AI tissue collaboration

Pharmacology-AI, a platform uniting tissue models with machine learning

🔶 Pharmacology-AI analyzes your patient metadata, genomic/transcriptomic data or preclinical biomarker data to identify inter-individual differences that can affect patient outcomes.

REPROCELL, IBM, and the STFC Hartree Centre have developed Pharmacology-AI, a platform uniting tissue models with machine learning. Delivered through the Hartree National Centre for Digital Innovation, it reduces costs, enhances trial design, and enables more targeted therapies (AI-tissue collaboration could transform drug trials and precision medicine).

At the center of this platform is REPROCELL’s human fresh tissue models–which preserve the biological complexity of real patient samples. These models allow researchers to simulate drug effects before clinical trials, generating data that is both reliable and highly relevant (AI meets human tissue to fast-track precision medicine development).

When used as a stand-alone platform or when combined with human living tissue data, Pharmacology-AI can help identify the optimum patient population for your drug therapy. This allows you to:

• ✅ Identify patient profiles most likely to benefit from future trials,

• ✅ Enable smarter clinical trial design, and

• ✅ Improve the chances of clinical trial success.

XtalPi’s collaboration with PharmaEngine

XtalPi’s AI Collaboration with PharmaEngine Reaches Milestone ⛳ as Novel PRMT5 Inhibitor PEP08 Receives Clinical Trial Approvals

XtalPi has received regulatory clearances to initiate Phase 1 clinical trials in solid tumors with PEP08, a next-generation PRMT5 inhibitor candidate developed through its AI drug discovery collaboration with PharmaEngine.

Approvals include Australia's Human Research Ethics Committee (HREC), recognized by the Australian Therapeutic Goods Administration (TGA), and the food and drug authority of the Taiwan region (TFDA). 

On September 9, 2025, Xtalpi Inc (Stock Code: 2228.HK) announced that PEP08, a next-generation PRMT5 inhibitor candidate developed through its AI drug discovery collaboration with PharmaEngine, Inc headquartered in Taipei (TWO:4162), has received regulatory clearances to initiate Phase 1 clinical trials in solid tumors. Approvals include Australia's 🦘 Human Research Ethics Committee (HREC), recognized by the Australian Therapeutic Goods Administration (TGA), and the food and drug authority of the Taiwan region 🇹🇼 (TFDA). This milestone triggered a payment to XtalPi under the partnership agreement (XtalPi AI Drug Discovery Collaboration Reaches Milestone as PharmaEngine's Novel PRMT5 Inhibitor PEP08 Receives Clinical Trial Approvals).

• ➡️ PRMT5 (Protein Arginine Methyltransferase 5) is a validated synthetic lethality target in tumors harboring homozygous MTAP deletion, which is related to poor prognosis and present in 1️⃣0️⃣-1️⃣5️⃣% of human cancers, including small cell lung cancer (NSCLC), mesothelioma, pancreatic cancer, glioblastoma multiforme (GBM), head and neck cancer, esophageal cancer, and bladder cancer.

• ➡️ Following iterative optimization through quantum physics and AI-powered ADMET screening, PEP08 emerged as the preclinical candidate (PCC) and advanced through IND-enabling studies by PharmaEngine.

• ➡️ Preclinical studies revealed PEP08's markedly improved safety profile compared to first-generation PRMT5 inhibitors, alongside favorable blood-brain barrier penetration and overall developability characteristics. The compound achieved robust in vivo efficacy across multiple animal models. Compared to other clinical-stage second-generation candidates, PEP08 exhibits potential best-in-class properties and compelling combination therapy opportunities.

Lunai Bioworks

Lunai Bioworks

Lunai Bioworks launched a transformer-based platform that embeds biological risk intelligence directly into large language model (LLM) pipeline, creating a dual-value proposition: ▶️ accelerating therapeutic development while simultaneously providing biodefense capabilities.

Lunai Bioworks' solution embeds a proprietary neurotoxicity intelligence layer into LLM workflows, ensuring safety while preserving innovation.

On September 9, 2025, Lunai Bioworks (that on August 27, 2025, Renovaro Inc, NASDAQ:RENB, announced that it will change its corporate name to Lunai Bioworks, Inc) announced the launch of a transformer-based platform that embeds biological risk intelligence directly into large language model (LLM) pipelines (First-Ever AI Safety Platform: Lunai Bioworks Launches Transformer Tech to Secure Drug Discovery & Block Biothreat).

This breakthrough uses virtual chemical screening to identify novel compounds as being potentially toxic, expediting therapeutic discovery and development. Through its application, this platform also addresses a growing security concern, the misuse of generative AI in designing hazardous biological or chemical compounds.

Background

Back on June 30, 2025, Lunai’s (NASDAQ:RENB) wholly owned subsidiary BioSymetrics has unveiled a proprietary AI-based zebrafish screening platform designed to rapidly identify medical countermeasures for neurotoxic chemical agents, ➡️ including weaponized substances like Sarin (Renovaro Launches AI-Based Neurotoxin Countermeasure Initiative Addressing Emerging National Security Needs). The platform was integrated into Lunai’s Defense Countermeasures Program, marking a strategic entry into the dual-use biotechnology and biodefense sector.

Also during this sumner (July 2025), Lunai announced a significant financial restructuring where senior debt holders agreed to convert approximately 💲9️⃣.7️⃣M of outstanding senior debt into equity. The conversion will result in the issuance of approximately 53.6 million shares of common stock at 💲0.30 per share (AI Healthcare Pioneer Renovaro Eliminates $9.7M Debt Through Strategic Conversion to Power Growth).

Then on September 8, 2025 Lunai Bioworks reaffirmed its long-term commitment to European markets and partnerships while announcing the elimination of its legacy subsidiary, Gedi Cube B.V., which has entered bankruptcy proceedings in the Netherlands (Lunai Bioworks Strengthens European Strategy Through Restructuring).

The company is known for introducing ✴️Augusta✴️, an advanced AI platform designed to transform neurology by enabling precision diagnostics and treatment for complex neurological disorders. By integrating multimodal data (imaging, genomics, clinical records), Augusta aims to accelerate research and personalize therapies for conditions like Alzheimer's, Parkinson’s, and epilepsy (Renovaro Launches Augusta, an AI-Powered Precision Neurology Platform).

Finally on April 22, 2025, Lunai announced that it is expanding its ongoing strategic collaboration with Nebul, a leading AI cloud infrastructure company, to advance the early detection of cancer and other diseases (Renovaro Secures High-Powered Computing from Nebul Through).

Korea and quantum-AI drug project

Korea backs Samjin in 💲9️⃣M quantum-AI drug project

Samjin Pharmaceutical has been selected by the Korean government to develop a drug discovery platform that combines quantum computing with AI, the Q-DrugX (Quantum Drug Exploration) system (for binding prediction and candidate selection).

Samjin Pharmaceutical has been selected by the Korean government to lead a four-and-a-half-year, 12.75 billion won ($9.2M) project to develop a drug discovery platform that combines quantum computing with AI (Korea backs Samjin in $9 mil. quantum-AI drug project). The company will build out its Q-DrugX (Quantum Drug Exploration) system, designed to run high-precision binding simulations and generative AI modeling, with the aim of unlocking targets previously considered “undruggable.”

The consortium includes Quantum Intelligence and Namu ICT on target discovery, Gwangju Institute of Science and Technology on molecular optimization, and Seoul National University Hospital on preclinical and early clinical validation.

Samjin Pharmaceutical Co., Ltd (005500.KS), a leading pharmaceutical company in Korea established in 1968, is dedicated to pioneering advancements in therapeutic innovation. It offers medicine in oral, drop, and injecting forms.

• 🔶 The company provides over-the-counter medicines, such as Gevorin, an anti-infalammatory pain killer; Trestan, an appetite stimulant; Flaris, an anti-thrombotic agent; and Nutilin, a brain function improvement agent, as well as medicine for treatment of chronic diseases.

• 🔶 It also develops SA001, which is in Phase II clinical trial for the treatment for dry eye syndrome and Sjogren syndrome; SJP1804 medicine that is Phase I clinical trial to treat macular degeneration; and SJP1604, which is in Phase I clinical trial for cancer; SJP1901 and SJP1902 for cancer treatment; SJP 1801 to treat Alzheimer's and Parkinson's disease; SJP006, an anti-viral product; and SJP003 for treatment of diabetes. In addition, the company's preclinical product is SJP1602 for the treatment of cancer.

In 2023, Samjin Pharmaceutical and InCerebro joined forces to develop new drugs using AI. inCerebro in Seoul, Korea is a pharmaceutical research and development company combining AI with physics-based methods. The company's proprietary MIND platform (MIND-A, MIND-B, MIND-S and MIND-Q) is specifically designed to identify novel small molecule therapeutics for difficult targets like GPCRs and previously intractable protein targets, by combining key technologies such as QM/MM docking, water pharmacophore, automatic globular/membrane MD, AI-driven BAR free energy and Qcharge-VM2 free energy.

Luminari CRO Launches Revolutionary AI-Powered Platform to Transform Clinical Trial Efficiency and Drug Development

Luminari CRO announced its official launch with a groundbreaking AI-powered platform and simultaneously opened its 💲2️⃣M pre-seed 🌱 funding round on Hey Canopy and unveiled a strategic collaboration with 20/15 Visioneers.

On September 5, 2025, Luminari CRO, a pioneering clinical research organization, announced its official launch with a groundbreaking AI-powered platform designed to revolutionize drug development and clinical trial processes. The company is simultaneously opening its $2M pre-seed funding round on Hey Canopy and unveiling a strategic collaboration with 20/15 Visioneers, a leader in science and technology consulting and marketing (Luminari CRO Launches Revolutionary AI-Powered Platform to Transform Clinical Trial Efficiency and Drug Development).

Luminari is transforming drug development with AI-powered digital twins and blockchain technology to accelerate clinical trials and overcome challenges. By utilizing their Digital Twin AI technologies they can reduce clinical trial costs, errors and delays:

• ✂️ Cut Regulatory Document preparation time from 8 weeks to 8 minutes!

• ⬇️ Reduce Protocol Development that traditionally takes about 8 weeks and 3-5 specialists to just minutes with a single team member!

Basically they reduce drug-market entry time via:

❇️ Expedited regulatory submissions,
❇️ Enhanced disease diagnosis with AI models, and
❇️ Hastened Patient Recruitment.

Overall, at the core of Luminari CRO’s offering is a sophisticated AI-driven platform that creates virtual patient models to predict study outcomes and success rates. This technology enables pharmaceutical companies to:

• Dramatically reduce protocol development timelines,

• Minimize costly trial failures through predictive modeling,

• Optimize patient recruitment and retention strategies,

• Enhance regulatory submission accuracy, and

• Streamline the entire drug development journey.

Ask them for a Free Trial before trial availability runs out!

BullFrog and Eleison Pharmaceuticals collaboration

BullFrog Delivers Real-World Impact in Eleison Pharmaceuticals Collaboration

BullFrog AI Holdings, Inc provided an update on its collaboration with Eleison Pharmaceuticals Inc.

On September 08, 2025, BullFrog AI Holdings, Inc (NASDAQ: BFRG; BFRGW) provided an update on its collaboration with Eleison Pharmaceuticals Inc, a Phase 3 oncology company focused on novel chemotherapeutic treatments for rare cancers (BullFrog AI’s bfPREP™ and bfLEAP® Platforms Deliver Real-World Impact in Eleison Pharmaceuticals Collaboration). The two entered initially in collaboration on February 27, 2025 (BullFrog AI and Eleison Pharmaceuticals Enter Agreement to Collaborate to Optimize Pivotal Phase 3 Trial).

• ✅ To support this collaboration, BullFrog AI developed a new data ingestion module, purpose-built to handle the scale and complexity of Eleison’s historical clinical data.

• ✅ Originally created to convert more than 1️⃣0️⃣,0️⃣0️⃣0️⃣ pages of clinical trial PDFs into an OMOP-standardized dataset for Eleison, the module proved so effective that it has since become a standalone commercial offering of BullFrog AI called bfPREP^™.

Bullfrog AI Holdings Inc, through its subsidiaries, operates as a digital biopharmaceutical company that focuses on AI/ML driven analysis of data sets in medicine and healthcare in the United States. bfLEAP™, developed at the prestigious Johns Hopkins University Applied Physics Laboratory and exclusively licensed to BullFrog AI, is a unique graph analytic AI platform that rapidly detects anomalies and uncovers hidden associations within disparate, multimodal, and incomplete data sets.

• At its core, the bfLEAP™ platform designed for biological and clinical data sets, is creating comprehensive data networks ready for in-depth analysis, and can be used for drug discovery, patient segmentation, drug repurposing, target discovery, and enhanced clinical trial analysis.

On June 12, 2025, BullFrog announced a strategic collaboration with Sygnature Discovery, a leading UK-based contract research organization (CRO) specializing in drug discovery, that will introduce BullFrog Data Networks™ to Sygnature’s global client base of relevant biopharma companies. The collaboration is expected to greatly accelerate brand recognition and user uptake to generate between 💲1️⃣5️⃣-💲3️⃣0️⃣ M in revenue for BullFrog AI through 2028 (BullFrog AI Announces Strategic Collaboration with Sygnature Discovery to Introduce BullFrog Data Networks™ to Global Biopharma Clients).

• The BullFrog Data Networks™ accelerates the exploration of complex, high-dimensional, multi-modal datasets, uncovering hidden relationships and novel pathways critical to understanding disease biology. The platform supports vital research applications including early target identification, mechanism-of-action elucidation, patient stratification, drug repurposing, and clinical trial optimization.

During 2024, BullFrog announced significant advancements in its collaboration with the Lieber Institute for Brain Development (LIBD), including the identification of potential drug targets for multiple neuropsychiatric conditions. Finally, apart from the LIBD collaboration progression, on October 09, 2024, BullFrog AI Announced Publication of Data Supporting Potential of Liver Disease Treatment Candidate BF-114.